CMS Okays Payment for Novel AI Prostate Test

Medicare will now cover an AI-based test for prostate cancer that predicts which men will benefit from androgen deprivation therapy. The Centers for Medicare & Medicare Services approved the payment rate for ArteraAI as a clinical diagnostic test. The test improves risk stratification and personalizes treatment. It combines a patient’s clinical and pathologic information into…

Read More

ED interrogates Jharkhand IAS officer’s wife

An Indian Administrative Service (IAS) officer’s wife from Jharkhand is being interrogated by the Enforcement Directorate (ED) in connection with the Berlin Hospital Land case. This case involves alleged irregularities in the acquisition of land in Germany for a hospital project. The ED is investigating potential financial misconduct and illegal transactions related to the case….

Read More

Medical Innovation Must Shift Focus From Common Problems to Unsolvable Ones

The economics of healthcare have historically driven innovation in common conditions with high patient volumes, such as cardiovascular disease. However, as technology grows more sophisticated, the focus in medical discovery is shifting towards solving previously considered impossible problems. Advancements in surgical technology are redefining the boundaries between possible and impossible, particularly in repairing microscopic anatomy…

Read More

Polypharmacy project improves patient care

A cross-border project called iSIMPATYHY has led to improved patient safety by reducing adverse drug reactions. The project, which involved health services in Ireland, Northern Ireland, and Scotland, trained additional healthcare professionals in polypharmacy and medicines reviews. The project resulted in over 2,500 comprehensive medicines reviews by pharmacists in GP practices in border counties. As…

Read More

Polycystic Ovary Syndrome Status Unrelated to Fertility Treatment Births

Fertility treatment-attributed births are similar among patients with and without polycystic ovary syndrome (PCOS) regardless of fertility treatment pathway. A study found that despite the variety of available treatment options, the effectiveness of different treatment pathways remains unclear. Patients with PCOS were more likely to start their treatment with ovulation induction and were less likely…

Read More

Zeta Surgical mixed reality navigation gets FDA special 510(k) clearance

Zeta Surgical, a company specializing in surgical robotics and mixed reality, has obtained FDA special 510(k) clearance for its cranial navigation system for neurosurgery. The system offers real-time guidance with millimeter precision, eliminating the need for general anesthesia and rigid skull immobilization. The Special 510(k) clearance covers workflow and performance enhancements, such as streamlined navigation…

Read More

Alex Azar’s Unusual Spin Through the Revolving Door

Former Health and Human Services secretary Alex Azar, who spent a decade with pharmaceutical giant Eli Lilly and Co, has now become the chairman of the board of a company trying to make prescription drug imports happen. The company, LifeScience Logistics, is managing Florida’s Canadian importation program and is being paid $39 million by the…

Read More

Surgeon shares tips for incorporating botulinum toxins into ophthalmic practice

In a presentation at Hawaiian Eye/Retina 2024, Dr. Joely Kaufman discussed the differences between the five available botulinum toxins for treating glabellar muscle contraction. She advises starting with just one toxin to get used to it before incorporating others. She also highlighted five common glabellar contraction patterns and emphasized the importance of dosing based on…

Read More

Arena BioWorks launches in Cambridge to speed drug discovery

A new biomedical institute called Arena BioWorks is being launched in Cambridge’s Kendall Square, with $500 million in private funding. The institute aims to shorten the time from research to life-saving medicines by combining drug discovery and company creation under one roof. This model challenges the traditional separation of academic research and venture-backed drug development….

Read More
error: Content is protected !!